Global Novel Drug Delivery Systems

Novel Drug Delivery Systems Comprehensive Study by Type (Liposomes, PEGylated Proteins & Polypeptides, Polymer Nanoparticle, Protein Drug Conjugates, Others), Application (Hospitals & Clinic, Cancer Treatment Centers, Others), Drug (Oral Drug, Pulmonary Drug, Transdermal Drug, Injectable Drug, Others), Mode (Modulated Drug Delivery Systems, Targeted Drug Delivery Systems (Active Targeting, Passive Targeting), Controlled Drug Delivery Systems) Players and Region - Global Market Outlook to 2027

Novel Drug Delivery Systems Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Novel Drug Delivery Systems
A well-designed Novel Drug Delivery System may be a significant step forward in addressing issues relating to drug release at a particular location and at a specific time. Pharmaceutical firms are investing in the development of new drug delivery technologies in order to bring medications to patients more effectively and with less side effects. The transition of an actual drug molecule from a standard form to a novel delivery mechanism will increase patient compliance, safety, and efficacy dramatically. An endogenous drug molecule can be given a new lease on life in the form of a Novel Drug Delivery System. Latest advancements in medication pharmacokinetic and pharmacodynamic activity have developed a more realistic approach to designing an effective drug delivery method.

AttributesDetails
Study Period2017-2027
Base Year2021
High Growth MarketNorth America
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States & United Kingdom Players will contribute the maximum growth to Global Novel Drug Delivery Systems market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

AstraZeneca PLC (United States), Bayer AG (Germany), Pfizer Inc. (United States), Serum Institute (India), Abbott Laboratories (United States), F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline PLC (United Kingdom), Johnson & Johnson (United States), Merck & Co. Inc. (Germany) and Novartis AG (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Sanofi SA (France), SHL Medical (Switzerland) and Bharat Biotech (India).

Segmentation Overview
AMA Research has segmented the market of Global Novel Drug Delivery Systems market by Type (Liposomes, PEGylated Proteins & Polypeptides, Polymer Nanoparticle, Protein Drug Conjugates and Others), Application (Hospitals & Clinic, Cancer Treatment Centers and Others) and Region.



On the basis of geography, the market of Novel Drug Delivery Systems has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Asia Pacific region held largest market share in the year 2021. If we see Market by Drug, the sub-segment i.e. Oral Drug will boost the Novel Drug Delivery Systems market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Mode, the sub-segment i.e. Modulated Drug Delivery Systems will boost the Novel Drug Delivery Systems market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies

In 2021, Thermo Fisher Scientific Company launches a new IVD system for assay developers and clinical laboratories to accelerate molecular diagnostics growth. and In 2020, IDEAYA Biosciences, Inc. and GlaxoSmithKline plc. (GSK) has announced a strategic partnership to develop solutions for the field of oncology.
European Union, Medical Device Regulation (2017/745) – According to Article 117 Prescriptions That Have A Computer as Part of The Package Such as Pre-Filled Syringes and Pens, Patches for Transdermal Drug Delivery and Pre-Filled Inhalers, Etc. The Marketing Authorization Application or Variation Application Should Include A CE Certificate or Declaration of Conformity for The Device Whether it is CE Marked. and Unite States, FDA “Transdermal and Topical Delivery Systems – Product Development and Quality Considerations” – Provides Guidelines for Design and Quality Standards along with Recommendations To Applicants and Manufacturers of Transdermal And Topical Delivery Systems (TDS) for the Sale Across the United States.

Market Drivers
  • Growing Demand for Controlled Release Drugs
  • Demand for Oral Drug Delivery
  • Prevalence of Novel Diseases Including Covid-19 and Ebola

Opportunities
  • Demand for Cost Effective & Efficient Novel Drug
  • Growth in Healthcare infrastructure Due to Pandemic

Restraints
  • Stability Concerns

Challenges
  • Lack of Trained Professionals


Key Target Audience
Novel Drug Manufactures, New Entrants and Investors, Novel Drug Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • Liposomes
  • PEGylated Proteins & Polypeptides
  • Polymer Nanoparticle
  • Protein Drug Conjugates
  • Others
By Application
  • Hospitals & Clinic
  • Cancer Treatment Centers
  • Others
By Drug
  • Oral Drug
  • Pulmonary Drug
  • Transdermal Drug
  • Injectable Drug
  • Others

By Mode
  • Modulated Drug Delivery Systems
  • Targeted Drug Delivery Systems (Active Targeting, Passive Targeting)
  • Controlled Drug Delivery Systems

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Demand for Controlled Release Drugs
      • 3.2.2. Demand for Oral Drug Delivery
      • 3.2.3. Prevalence of Novel Diseases Including Covid-19 and Ebola
    • 3.3. Market Challenges
      • 3.3.1. Lack of Trained Professionals
    • 3.4. Market Trends
      • 3.4.1. Technical Progress in Pharma Industry
      • 3.4.2. Heavy Investments in Research & Development
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Novel Drug Delivery Systems, by Type, Application, Drug, Mode and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Novel Drug Delivery Systems (Value)
      • 5.2.1. Global Novel Drug Delivery Systems by: Type (Value)
        • 5.2.1.1. Liposomes
        • 5.2.1.2. PEGylated Proteins & Polypeptides
        • 5.2.1.3. Polymer Nanoparticle
        • 5.2.1.4. Protein Drug Conjugates
        • 5.2.1.5. Others
      • 5.2.2. Global Novel Drug Delivery Systems by: Application (Value)
        • 5.2.2.1. Hospitals & Clinic
        • 5.2.2.2. Cancer Treatment Centers
        • 5.2.2.3. Others
      • 5.2.3. Global Novel Drug Delivery Systems by: Drug (Value)
        • 5.2.3.1. Oral Drug
        • 5.2.3.2. Pulmonary Drug
        • 5.2.3.3. Transdermal Drug
        • 5.2.3.4. Injectable Drug
        • 5.2.3.5. Others
      • 5.2.4. Global Novel Drug Delivery Systems by: Mode (Value)
        • 5.2.4.1. Modulated Drug Delivery Systems
        • 5.2.4.2. Targeted Drug Delivery Systems (Active Targeting, Passive Targeting)
        • 5.2.4.3. Controlled Drug Delivery Systems
      • 5.2.5. Global Novel Drug Delivery Systems Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Novel Drug Delivery Systems: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca PLC (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Serum Institute (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Abbott Laboratories (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GlaxoSmithKline PLC (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Johnson & Johnson (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck & Co. Inc. (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis AG (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Novel Drug Delivery Systems Sale, by Type, Application, Drug, Mode and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Novel Drug Delivery Systems (Value)
      • 7.2.1. Global Novel Drug Delivery Systems by: Type (Value)
        • 7.2.1.1. Liposomes
        • 7.2.1.2. PEGylated Proteins & Polypeptides
        • 7.2.1.3. Polymer Nanoparticle
        • 7.2.1.4. Protein Drug Conjugates
        • 7.2.1.5. Others
      • 7.2.2. Global Novel Drug Delivery Systems by: Application (Value)
        • 7.2.2.1. Hospitals & Clinic
        • 7.2.2.2. Cancer Treatment Centers
        • 7.2.2.3. Others
      • 7.2.3. Global Novel Drug Delivery Systems by: Drug (Value)
        • 7.2.3.1. Oral Drug
        • 7.2.3.2. Pulmonary Drug
        • 7.2.3.3. Transdermal Drug
        • 7.2.3.4. Injectable Drug
        • 7.2.3.5. Others
      • 7.2.4. Global Novel Drug Delivery Systems by: Mode (Value)
        • 7.2.4.1. Modulated Drug Delivery Systems
        • 7.2.4.2. Targeted Drug Delivery Systems (Active Targeting, Passive Targeting)
        • 7.2.4.3. Controlled Drug Delivery Systems
      • 7.2.5. Global Novel Drug Delivery Systems Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Novel Drug Delivery Systems: by Type(USD Million)
  • Table 2. Novel Drug Delivery Systems Liposomes , by Region USD Million (2016-2021)
  • Table 3. Novel Drug Delivery Systems PEGylated Proteins & Polypeptides , by Region USD Million (2016-2021)
  • Table 4. Novel Drug Delivery Systems Polymer Nanoparticle , by Region USD Million (2016-2021)
  • Table 5. Novel Drug Delivery Systems Protein Drug Conjugates , by Region USD Million (2016-2021)
  • Table 6. Novel Drug Delivery Systems Others , by Region USD Million (2016-2021)
  • Table 7. Novel Drug Delivery Systems: by Application(USD Million)
  • Table 8. Novel Drug Delivery Systems Hospitals & Clinic , by Region USD Million (2016-2021)
  • Table 9. Novel Drug Delivery Systems Cancer Treatment Centers , by Region USD Million (2016-2021)
  • Table 10. Novel Drug Delivery Systems Others , by Region USD Million (2016-2021)
  • Table 11. Novel Drug Delivery Systems: by Drug(USD Million)
  • Table 12. Novel Drug Delivery Systems Oral Drug , by Region USD Million (2016-2021)
  • Table 13. Novel Drug Delivery Systems Pulmonary Drug , by Region USD Million (2016-2021)
  • Table 14. Novel Drug Delivery Systems Transdermal Drug , by Region USD Million (2016-2021)
  • Table 15. Novel Drug Delivery Systems Injectable Drug , by Region USD Million (2016-2021)
  • Table 16. Novel Drug Delivery Systems Others , by Region USD Million (2016-2021)
  • Table 17. Novel Drug Delivery Systems: by Mode(USD Million)
  • Table 18. Novel Drug Delivery Systems Modulated Drug Delivery Systems , by Region USD Million (2016-2021)
  • Table 19. Novel Drug Delivery Systems Targeted Drug Delivery Systems (Active Targeting, Passive Targeting) , by Region USD Million (2016-2021)
  • Table 20. Novel Drug Delivery Systems Controlled Drug Delivery Systems , by Region USD Million (2016-2021)
  • Table 21. South America Novel Drug Delivery Systems, by Country USD Million (2016-2021)
  • Table 22. South America Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 23. South America Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 24. South America Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 25. South America Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 26. Brazil Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 27. Brazil Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 28. Brazil Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 29. Brazil Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 30. Argentina Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 31. Argentina Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 32. Argentina Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 33. Argentina Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 34. Rest of South America Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 35. Rest of South America Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 36. Rest of South America Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 37. Rest of South America Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 38. Asia Pacific Novel Drug Delivery Systems, by Country USD Million (2016-2021)
  • Table 39. Asia Pacific Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 40. Asia Pacific Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 41. Asia Pacific Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 42. Asia Pacific Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 43. China Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 44. China Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 45. China Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 46. China Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 47. Japan Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 48. Japan Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 49. Japan Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 50. Japan Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 51. India Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 52. India Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 53. India Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 54. India Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 55. South Korea Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 56. South Korea Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 57. South Korea Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 58. South Korea Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 59. Taiwan Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 60. Taiwan Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 61. Taiwan Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 62. Taiwan Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 63. Australia Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 64. Australia Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 65. Australia Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 66. Australia Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 67. Rest of Asia-Pacific Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 68. Rest of Asia-Pacific Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 69. Rest of Asia-Pacific Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 70. Rest of Asia-Pacific Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 71. Europe Novel Drug Delivery Systems, by Country USD Million (2016-2021)
  • Table 72. Europe Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 73. Europe Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 74. Europe Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 75. Europe Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 76. Germany Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 77. Germany Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 78. Germany Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 79. Germany Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 80. France Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 81. France Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 82. France Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 83. France Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 84. Italy Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 85. Italy Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 86. Italy Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 87. Italy Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 88. United Kingdom Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 89. United Kingdom Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 90. United Kingdom Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 91. United Kingdom Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 92. Netherlands Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 93. Netherlands Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 94. Netherlands Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 95. Netherlands Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 96. Rest of Europe Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 97. Rest of Europe Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 98. Rest of Europe Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 99. Rest of Europe Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 100. MEA Novel Drug Delivery Systems, by Country USD Million (2016-2021)
  • Table 101. MEA Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 102. MEA Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 103. MEA Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 104. MEA Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 105. Middle East Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 106. Middle East Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 107. Middle East Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 108. Middle East Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 109. Africa Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 110. Africa Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 111. Africa Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 112. Africa Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 113. North America Novel Drug Delivery Systems, by Country USD Million (2016-2021)
  • Table 114. North America Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 115. North America Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 116. North America Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 117. North America Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 118. United States Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 119. United States Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 120. United States Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 121. United States Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 122. Canada Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 123. Canada Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 124. Canada Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 125. Canada Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 126. Mexico Novel Drug Delivery Systems, by Type USD Million (2016-2021)
  • Table 127. Mexico Novel Drug Delivery Systems, by Application USD Million (2016-2021)
  • Table 128. Mexico Novel Drug Delivery Systems, by Drug USD Million (2016-2021)
  • Table 129. Mexico Novel Drug Delivery Systems, by Mode USD Million (2016-2021)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Novel Drug Delivery Systems: by Type(USD Million)
  • Table 141. Novel Drug Delivery Systems Liposomes , by Region USD Million (2022-2027)
  • Table 142. Novel Drug Delivery Systems PEGylated Proteins & Polypeptides , by Region USD Million (2022-2027)
  • Table 143. Novel Drug Delivery Systems Polymer Nanoparticle , by Region USD Million (2022-2027)
  • Table 144. Novel Drug Delivery Systems Protein Drug Conjugates , by Region USD Million (2022-2027)
  • Table 145. Novel Drug Delivery Systems Others , by Region USD Million (2022-2027)
  • Table 146. Novel Drug Delivery Systems: by Application(USD Million)
  • Table 147. Novel Drug Delivery Systems Hospitals & Clinic , by Region USD Million (2022-2027)
  • Table 148. Novel Drug Delivery Systems Cancer Treatment Centers , by Region USD Million (2022-2027)
  • Table 149. Novel Drug Delivery Systems Others , by Region USD Million (2022-2027)
  • Table 150. Novel Drug Delivery Systems: by Drug(USD Million)
  • Table 151. Novel Drug Delivery Systems Oral Drug , by Region USD Million (2022-2027)
  • Table 152. Novel Drug Delivery Systems Pulmonary Drug , by Region USD Million (2022-2027)
  • Table 153. Novel Drug Delivery Systems Transdermal Drug , by Region USD Million (2022-2027)
  • Table 154. Novel Drug Delivery Systems Injectable Drug , by Region USD Million (2022-2027)
  • Table 155. Novel Drug Delivery Systems Others , by Region USD Million (2022-2027)
  • Table 156. Novel Drug Delivery Systems: by Mode(USD Million)
  • Table 157. Novel Drug Delivery Systems Modulated Drug Delivery Systems , by Region USD Million (2022-2027)
  • Table 158. Novel Drug Delivery Systems Targeted Drug Delivery Systems (Active Targeting, Passive Targeting) , by Region USD Million (2022-2027)
  • Table 159. Novel Drug Delivery Systems Controlled Drug Delivery Systems , by Region USD Million (2022-2027)
  • Table 160. South America Novel Drug Delivery Systems, by Country USD Million (2022-2027)
  • Table 161. South America Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 162. South America Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 163. South America Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 164. South America Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 165. Brazil Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 166. Brazil Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 167. Brazil Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 168. Brazil Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 169. Argentina Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 170. Argentina Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 171. Argentina Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 172. Argentina Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 173. Rest of South America Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 174. Rest of South America Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 175. Rest of South America Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 176. Rest of South America Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 177. Asia Pacific Novel Drug Delivery Systems, by Country USD Million (2022-2027)
  • Table 178. Asia Pacific Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 179. Asia Pacific Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 180. Asia Pacific Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 181. Asia Pacific Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 182. China Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 183. China Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 184. China Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 185. China Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 186. Japan Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 187. Japan Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 188. Japan Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 189. Japan Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 190. India Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 191. India Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 192. India Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 193. India Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 194. South Korea Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 195. South Korea Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 196. South Korea Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 197. South Korea Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 198. Taiwan Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 199. Taiwan Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 200. Taiwan Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 201. Taiwan Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 202. Australia Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 203. Australia Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 204. Australia Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 205. Australia Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 206. Rest of Asia-Pacific Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 207. Rest of Asia-Pacific Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 208. Rest of Asia-Pacific Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 209. Rest of Asia-Pacific Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 210. Europe Novel Drug Delivery Systems, by Country USD Million (2022-2027)
  • Table 211. Europe Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 212. Europe Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 213. Europe Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 214. Europe Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 215. Germany Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 216. Germany Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 217. Germany Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 218. Germany Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 219. France Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 220. France Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 221. France Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 222. France Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 223. Italy Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 224. Italy Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 225. Italy Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 226. Italy Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 227. United Kingdom Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 228. United Kingdom Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 229. United Kingdom Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 230. United Kingdom Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 231. Netherlands Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 232. Netherlands Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 233. Netherlands Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 234. Netherlands Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 235. Rest of Europe Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 236. Rest of Europe Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 237. Rest of Europe Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 238. Rest of Europe Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 239. MEA Novel Drug Delivery Systems, by Country USD Million (2022-2027)
  • Table 240. MEA Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 241. MEA Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 242. MEA Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 243. MEA Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 244. Middle East Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 245. Middle East Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 246. Middle East Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 247. Middle East Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 248. Africa Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 249. Africa Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 250. Africa Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 251. Africa Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 252. North America Novel Drug Delivery Systems, by Country USD Million (2022-2027)
  • Table 253. North America Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 254. North America Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 255. North America Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 256. North America Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 257. United States Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 258. United States Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 259. United States Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 260. United States Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 261. Canada Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 262. Canada Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 263. Canada Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 264. Canada Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 265. Mexico Novel Drug Delivery Systems, by Type USD Million (2022-2027)
  • Table 266. Mexico Novel Drug Delivery Systems, by Application USD Million (2022-2027)
  • Table 267. Mexico Novel Drug Delivery Systems, by Drug USD Million (2022-2027)
  • Table 268. Mexico Novel Drug Delivery Systems, by Mode USD Million (2022-2027)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Novel Drug Delivery Systems: by Type USD Million (2016-2021)
  • Figure 5. Global Novel Drug Delivery Systems: by Application USD Million (2016-2021)
  • Figure 6. Global Novel Drug Delivery Systems: by Drug USD Million (2016-2021)
  • Figure 7. Global Novel Drug Delivery Systems: by Mode USD Million (2016-2021)
  • Figure 8. South America Novel Drug Delivery Systems Share (%), by Country
  • Figure 9. Asia Pacific Novel Drug Delivery Systems Share (%), by Country
  • Figure 10. Europe Novel Drug Delivery Systems Share (%), by Country
  • Figure 11. MEA Novel Drug Delivery Systems Share (%), by Country
  • Figure 12. North America Novel Drug Delivery Systems Share (%), by Country
  • Figure 13. Global Novel Drug Delivery Systems share by Players 2021 (%)
  • Figure 14. Global Novel Drug Delivery Systems share by Players (Top 3) 2021(%)
  • Figure 15. Global Novel Drug Delivery Systems share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. AstraZeneca PLC (United States) Revenue, Net Income and Gross profit
  • Figure 18. AstraZeneca PLC (United States) Revenue: by Geography 2021
  • Figure 19. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 20. Bayer AG (Germany) Revenue: by Geography 2021
  • Figure 21. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Pfizer Inc. (United States) Revenue: by Geography 2021
  • Figure 23. Serum Institute (India) Revenue, Net Income and Gross profit
  • Figure 24. Serum Institute (India) Revenue: by Geography 2021
  • Figure 25. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 26. Abbott Laboratories (United States) Revenue: by Geography 2021
  • Figure 27. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2021
  • Figure 29. GlaxoSmithKline PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. GlaxoSmithKline PLC (United Kingdom) Revenue: by Geography 2021
  • Figure 31. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 32. Johnson & Johnson (United States) Revenue: by Geography 2021
  • Figure 33. Merck & Co. Inc. (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Merck & Co. Inc. (Germany) Revenue: by Geography 2021
  • Figure 35. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Novartis AG (Switzerland) Revenue: by Geography 2021
  • Figure 37. Global Novel Drug Delivery Systems: by Type USD Million (2022-2027)
  • Figure 38. Global Novel Drug Delivery Systems: by Application USD Million (2022-2027)
  • Figure 39. Global Novel Drug Delivery Systems: by Drug USD Million (2022-2027)
  • Figure 40. Global Novel Drug Delivery Systems: by Mode USD Million (2022-2027)
  • Figure 41. South America Novel Drug Delivery Systems Share (%), by Country
  • Figure 42. Asia Pacific Novel Drug Delivery Systems Share (%), by Country
  • Figure 43. Europe Novel Drug Delivery Systems Share (%), by Country
  • Figure 44. MEA Novel Drug Delivery Systems Share (%), by Country
  • Figure 45. North America Novel Drug Delivery Systems Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AstraZeneca PLC (United States)
  • Bayer AG (Germany)
  • Pfizer Inc. (United States)
  • Serum Institute (India)
  • Abbott Laboratories (United States)
  • F. Hoffmann-La Roche AG (Switzerland)
  • GlaxoSmithKline PLC (United Kingdom)
  • Johnson & Johnson (United States)
  • Merck & Co. Inc. (Germany)
  • Novartis AG (Switzerland)
Additional players considered in the study are as follows:
Sanofi SA (France) , SHL Medical (Switzerland) , Bharat Biotech (India)
Select User Access Type

Key Highlights of Report


Jul 2022 169 Pages 95 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Novel Drug Delivery Systems Quantitative research analysis
Global Novel Drug Delivery Systems Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as AstraZeneca PLC (United States), Bayer AG (Germany), Pfizer Inc. (United States), Serum Institute (India), Abbott Laboratories (United States), F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline PLC (United Kingdom), Johnson & Johnson (United States), Merck & Co. Inc. (Germany) and Novartis AG (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technical Progress in Pharma Industry " is seen as one of major influencing trends for Novel Drug Delivery Systems Market during projected period 2021-2027.
The Novel Drug Delivery Systems market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Novel Drug Delivery Systems Report?

Have a Query? Click Here

Other Related Reports

Skin Ulcer Wound Care Products Comprehensive Study by Type (Pressure Ulcer, Diabetic Ulcer, Venous Ulcer, Arterial Ulcer), Application (Hospitals, Clinics, Others) Players and Region - Global Market ...
$ 3500
IV Fluids Comprehensive Study by Type (Colloids, Crystalloids, Blood and blood products, Oxygen-carrying solutions), Composition (Normal Saline {0.9% Normal Saline (0.9% NaCl}, Hypertonic saline {3, ...
$ 3650
Nelarabine Comprehensive Study by Application (Pregnancy, Nursing Mothers, Pediatric Use, Geriatric Use, Renal Impairment, Hepatic Impairment, Others), Distribution Channel (Online Channels, Offline ...
$ 3650
Degarelix Comprehensive Study by Type (120 mg per vial, 80 mg per vial), Application (Hospital, Drug store), Distribution Channel (Online, Offline) Players and Region - Global Market Outlook to 2028
$ 3500
Molecular Quality Controls Comprehensive Study by Type (Independent, Instrument Specific (DNA Sequencing)), Application (Infectious Diseases, Oncology, Genetic Tests, Other), End Users (IVD Manufactu...
$ 3450
Medical Specimen Bags Comprehensive Study by Type (Disposable, Reusable), Application (Hospitals, Clinics, Laboratory, Home Care, Other), Distribution Channel (Hospital Pharmacies, Online Pharmacies,...
$ 3350